Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

Peters, Solange ; Dafni, Urania ; Boyer, Michael ; De Ruysscher, Dirk ; Faivre-Finn, Corinne ; Felip, Enriqueta ; Garrido, Pilar ; Girard, Nicolas ; Guckenberger, Matthias ; Haanen, John ; Le Pechoux, Cecile ; Mornex, Francoise ; Ozsahin, Mahmut ; Paz-Ares, Luis ; Planchard, David ; Raben, David ; Ramalingam, Suresh ; Reck, Martin ; Smit, Egbert ; Stahel, Rolf ; Stenzinger, Albrecht ; Swanton, Charlie ; Vallone, Stefania ; Garassino, Marina C

[1]  Kyung Won Lee,et al.  Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[3]  P. Ascierto,et al.  CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Joon-Oh Park,et al.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer , 2018, Nature Medicine.

[5]  J. Lacy,et al.  RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. , 2018 .

[6]  K. Delman,et al.  Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma , 2018, Oncoimmunology.

[7]  Jingting Jiang,et al.  Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma , 2018, EBioMedicine.

[8]  J Bogaerts,et al.  ESMO-Magnitude of Clinical Benefit Scale version 1.1 , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  M. Kokubo,et al.  Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients , 2017, Scientific Reports.

[10]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[11]  Y. Bang,et al.  KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer. , 2017 .

[12]  M. Shah,et al.  Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial , 2017, JAMA oncology.

[13]  Jeffrey A. Engelman,et al.  Prospects for combining targeted and conventional cancer therapy with immunotherapy , 2017, Nature Reviews Cancer.

[14]  J. Ajani,et al.  Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer. , 2017 .

[15]  R. Grützmann,et al.  PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. , 2016, European journal of cancer.

[16]  G. Freeman,et al.  Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers , 2016, Oncotarget.

[17]  R. Weissleder,et al.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.

[18]  N. Chen,et al.  Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer , 2016, Scientific Reports.

[19]  M. Piccart,et al.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[21]  Johann A. Gagnon-Bartsch,et al.  Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas , 2014, Gut.

[22]  A. Wotherspoon,et al.  Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial , 2013, The Lancet. Oncology.

[23]  Galina Kurteva,et al.  Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. , 2013, The Lancet. Oncology.

[24]  S. Lagakos.  The challenge of subgroup analyses--reporting without distorting. , 2006, The New England journal of medicine.

[25]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[26]  Y. Maehara,et al.  The Significance of the PD‐L1 Expression in Non–Small‐Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers , 2018, Clinical lung cancer.

[27]  Y. Maehara,et al.  Combination Therapy of Radiotherapy and Anti‐PD‐1/PD‐L1 Treatment in Non–Small‐cell Lung Cancer: A Mini‐review , 2018, Clinical lung cancer.

[28]  G. Coukos,et al.  Radiotherapy combination opportunities leveraging immunity for the next oncology practice , 2017, CA: a cancer journal for clinicians.